Insider Trading History of Deschamps Philippe

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Deschamps Philippe since 2017. This trader's CIK number is 1638231. At the time of last reporting, Deschamps Philippe was the Officer of Coeptis Therapeutics Holdings, Inc.. (stock ticker symbol COEP). Also see all insider trading activities at Coeptis Therapeutics Holdings, Inc..

Note that in the past Deschamps Philippe also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Helius Medical Technologies, Inc. (HSDT) by Deschamps Philippe

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2019 HSDT 0 $0 0 $0 5,018 $28,100
2017 HSDT 127,551 $249,999 0 $0 0 $0

Yearly summary of insider trading at Coeptis Therapeutics Holdings, Inc. (COEP) by Deschamps Philippe

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2026 COEP 0 $0 0 $0 5,700 $60,192


Insider trading activities at 2 companies by Deschamps Philippe:

1. Helius Medical Technologies, Inc. (HSDT)

2. Coeptis Therapeutics Holdings, Inc. (COEP)

Table 1. Insider trading of Helius Medical Technologies, Inc. (HSDT) by Deschamps Philippe

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2019-04-05 HSDT Option Ex 5,018 5.60 28,100
2017-12-22 HSDT Buy 127,551 1.96 249,999

Table 2. Insider trading of Coeptis Therapeutics Holdings, Inc. (COEP) by Deschamps Philippe

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2026-02-11 COEP Option Ex 5,700 10.56 60,192

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Deschamps Philippe (Officer of Coeptis Therapeutics Holdings, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.